Related Experiment Video

Updated: Nov 6, 2025

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.4K

Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance

Sadegh Abbasian, Negin Shokrgozar, Gholamhossein Tamaddon

    Clinical Laboratory
    |May 12, 2021
    PubMed
    Abstract

    Insights

    SIRT1, a deacetylase, is increasingly expressed in chronic myeloid leukemia (CML) patients resistant to imatinib. Inhibiting SIRT1 may restore imatinib sensitivity, improving survival for CML patients.

    Area of Science:

    • Oncology
    • Hematology
    • Molecular Biology

    Background:

    • Chronic myeloid leukemia (CML) is driven by BCR-ABL tyrosine kinase activity.
    • Imatinib therapy improves survival but resistance can lead to relapse.
    • Drug resistance mechanisms include mutations, epigenetic changes, and receptor alterations.

    Purpose of the Study:

    • To investigate the role of SIRT1 in imatinib resistance in CML.
    • To explore SIRT1 as a potential therapeutic target for overcoming drug resistance.

    Main Methods:

    • Literature review of studies from PubMed, Scopus, and hematology journals.
    • Analysis of SIRT1 expression in CML patients with imatinib resistance.

    Main Results:

    • SIRT1 expression is elevated in imatinib-resistant CML patients.
    • The precise mechanism of SIRT1-mediated resistance requires further elucidation.
    • Inhibition of SIRT1 enhances CML cell sensitivity to imatinib.

    Conclusions:

    • SIRT1 is a significant factor contributing to drug resistance in CML.
    • Targeting SIRT1 may be a viable strategy to improve treatment outcomes for CML patients.
    • Understanding and neutralizing resistance factors like SIRT1 are crucial for patient survival.

    More Related Videos

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

    Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

    Published on: January 7, 2019

    8.4K
    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

    A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

    Published on: December 7, 2014

    15.0K

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.5K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    5.4K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    8.0K
    Cancer Stem Cells and Tumor Maintenance02:40

    Cancer Stem Cells and Tumor Maintenance

    Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
    Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
    5.2K
    Abnormal Proliferation02:23

    Abnormal Proliferation

    Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
    4.8K
    Electron Transport Chain: Complex I and II01:46

    Electron Transport Chain: Complex I and II

    The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
    ROS generation is regulated and maintained at moderate levels necessary...
    16.3K